Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16958056 | 0.86 | MAPT (0.50) | MEN1KMT2AMAPTNPC1TDP1 | |
| SCHEMBL16245017 | 0.85 | KMT2A (0.54) | MEN1KMT2AMAPTNPC1POLB | |
| SCHEMBL2385697 | 0.85 | NPC1 (0.68) | MEN1KMT2AMAPTNPC1TDP1 | |
| SCHEMBL9168360 | 0.84 | PLA2G2A (0.71) | PLA2G2ATP53PLA2G4B | |
| SCHEMBL6016562 | 0.83 | MAPT (0.59) | MEN1KMT2AMAPTNPC1TDP1 | |
| SCHEMBL11055090 | 0.83 | MAPT (0.59) | MEN1KMT2AMAPTNPC1TDP1 | |
| SCHEMBL1099548 | 0.82 | MEN1 (0.55) | MEN1KMT2AMAPTNPC1TDP1 | |
| SCHEMBL16960043 | 0.82 | MAPT (0.47) | MEN1KMT2AMAPTNPC1TDP1 | |
| SCHEMBL418688 | 0.81 | MAPK1 (0.55) | MEN1KMT2AMAPTKDM4EMAPK1 | |
| SCHEMBL2655120 | 0.81 | PLA2G2A (0.65) | MEN1KMT2AMAPTNPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223299-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-115645543-A | Maytansinoid derivatives, conjugates thereof, and methods of use | 里珍纳龙药品有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3273998-B1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMA (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3273998-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | Regeneron Pharmaceuticals, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| WO-2016160615-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | MEN1 876/4885KMT2A 3577/4885MAPT 3597/4885 |
| US-20250223299-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | MEN1 876/4885KMT2A 3577/4885MAPT 3597/4885 |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | MEN1 763/4885KMT2A 2980/4885MAPT 3649/4885 |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | MEN1 876/4885KMT2A 3577/4885MAPT 3597/4885 |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | SLC10A1, HNMT, OGFR | MEN1 876/4885KMT2A 3577/4885MAPT 3597/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | MEN1 876/4885KMT2A 3577/4885MAPT 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.